Cell Source, Inc. (CLCS)

Market Cap	47.84M +60.3%
Revenue (ttm)	n/a
Net Income	-6.57M
EPS	-0.16
Shares Out	48.82M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,173
Average Volume	7,645
Open	0.8433
Previous Close	0.9900
Day's Range	0.8433 - 0.9799
52-Week Range	0.1819 - 2.2500
Beta	-216.39
RSI	62.89
Earnings Date	Mar 20, 2026

About Cell Source

Cell Source, Inc., a biotechnology company, engages in developing cell therapy treatments based on the management of immune tolerance. Its lead product is the Veto Cell immune system management technology, which is an immune tolerance biotechnology that enables the selective blocking of immune responses. The company’s Veto Cell technology is used in various applications, including treatment of lymphoma, leukemia, and multiple myeloma through facilitation of the stem cell transplantation acceptance, as well as treatment of end stage kidney disea...

• Industry: Biotechnology
• Sector: Healthcare
• CEO: Itamar Shimrat
• Employees: 1
• Stock Exchange: OTCMKTS
• Ticker Symbol: CLCS